What is the recommended treatment regimen for minimal change disease?

Treatment of Minimal Change Disease

For initial treatment of minimal change disease in adults, start prednisone at 1 mg/kg/day (maximum 80 mg) or alternate-day dosing at 2 mg/kg (maximum 120 mg), continuing high-dose therapy for a minimum of 4 weeks if remission is achieved, or up to 16 weeks if remission is not achieved, followed by a slow taper over 6 months. 1

Initial Episode Treatment Algorithm

Adults

The KDIGO 2012 guidelines provide the strongest evidence base for initial therapy 1:

• Prednisone dosing: 1 mg/kg/day (max 80 mg) as single daily dose OR 2 mg/kg alternate-day (max 120 mg)
• Duration of high-dose therapy: Minimum 4 weeks if complete remission achieved; maximum 16 weeks if remission not achieved
• Tapering: Slow taper over 6 months after achieving remission
• Expected response: Over 80% achieve complete remission 2

For patients with contraindications to high-dose corticosteroids (uncontrolled diabetes, psychiatric conditions, severe osteoporosis), use oral cyclophosphamide or calcineurin inhibitors as first-line therapy 1.

Children

For pediatric patients, the KDOQI 2013 guidelines recommend 3:

• Initial therapy: Prednisone 60 mg/m² or 2 mg/kg daily (max 60 mg) until remission for at least 3 days
• Continuation: Alternate-day prednisone 40 mg/m² or 1.5 mg/kg (max 40 mg) for 2-5 months with tapering
• Key point: Extended therapy beyond 8 weeks decreases long-term relapse risk, though adherence becomes challenging

Treatment of Relapses

Infrequent Relapses

Use the same initial dose and duration as for first episode 1. Recent evidence suggests lower doses may be effective: prednisone 0.5 mg/kg can achieve remission with significantly reduced cumulative steroid exposure (1,191 mg vs 3,700 mg with standard dosing) 4.

Frequently Relapsing or Steroid-Dependent Disease

The treatment hierarchy for frequently relapsing/steroid-dependent MCD is:

1. Oral cyclophosphamide: 2-2.5 mg/kg/day for 8 weeks 1

2. Calcineurin inhibitors (if cyclophosphamide fails or fertility preservation desired):

   • Cyclosporine: 3-5 mg/kg/day in divided doses, target trough 80-120 ng/mL 1, 5, 6
   • Tacrolimus: 0.05-0.1 mg/kg/day in divided doses, target trough 5-10 ng/mL 6
   • Duration: 1-2 years, then slow taper 1, 5
   • Monitoring: Repeat renal biopsy at 12-24 months if creatinine rises >30% above baseline 5

3. Mycophenolate mofetil: 500-1,000 mg twice daily for 1-2 years (for patients intolerant of corticosteroids, cyclophosphamide, and CNIs) 1

4. Rituximab: Emerging as effective option for multiply relapsing disease 7, 8

Important Clinical Considerations

Calcineurin Inhibitor Selection

• Cyclosporine may be preferable in patients at risk for diabetes 6
• Tacrolimus preferred when cosmetic side effects of cyclosporine (hirsutism, gum hypertrophy) are unacceptable 6
• Both reduce steroid-related adverse effects (obesity, Cushing's syndrome, acne) compared to prednisone alone 9

Common Pitfalls to Avoid

Premature discontinuation of CNIs: Most patients relapse upon stopping CNI therapy. Continue for minimum 12 months after remission, then taper very slowly (by 0.5 mg/kg/month) 5. Rapid deterioration can occur even after years of treatment when CNI is stopped abruptly.

Inadequate initial steroid duration: Adults require longer treatment than children. Stopping before 4 weeks or not extending to 16 weeks in non-responders increases relapse risk 1.

Dosing steroids by actual weight in obese patients: Use ideal body weight to avoid unnecessary steroid exposure 3.

Using ACE inhibitors/ARBs for initial episode: These should NOT be used in normotensive patients to lower proteinuria during initial treatment 1. Reserve for hypertension management or persistent proteinuria despite immunosuppression.

Special Populations

Pregnancy: High-dose corticosteroids are hazardous to mother and fetus. Cyclosporine is less harmful and may control nephrotic syndrome 5. However, standard immunosuppressive therapy may still be necessary if complete remission is not achieved 10, 11.

Acute kidney injury: Treat with renal replacement therapy as indicated, but together with corticosteroids as for first episode 1.

Temporal Trends

Recent data shows treatment patterns have shifted since 2010 7:

• Decreased use of prednisone monotherapy and cyclophosphamide for relapses
• Increased use of CNIs (3-fold increase) and rituximab
• Remission rates remain high regardless of agent chosen

When to Consider Treatment Failure

• Adults: If no response after 6 months of CNI therapy (minimum 50% reduction in proteinuria), consider repeat biopsy to confirm diagnosis and switch to alternative therapy 5
• Children: Give CNI for at least 6 months before declaring treatment failure 5

The evidence strongly supports corticosteroids as first-line therapy with excellent response rates, but the availability of steroid-sparing agents (particularly CNIs and rituximab) provides effective alternatives for relapsing or steroid-intolerant patients while reducing cumulative steroid toxicity.